#NSCLC

All articles tagged with "NSCLC"

Median event-free survival reached 62.8 months with perioperative atezolizumab plus platinum-based chemotherapy versus 34.9 months with chemotherapy alone.
Pathological complete response was 29.6% versus 8.5%, and major pathological response was 53.6% versus 24.4%.
The Phase III IMpower030 trial did not meet its predefined statistical significance threshold, though investigators called the improvements clinically meaningful.
Benefits appeared consistent across independent review facility-assessed and investigator-assessed event-free survival, disease-free survival and overall survival.

DT Editorial Team·Sep 12, 2026·via medicalxpress.com

An investigational EGFR x HER3 antibody-drug conjugate, iza-bren, showed increasing clinical activity at higher dose levels in a randomized Phase I dose-expansion cohort.
At the recommended Phase III dose of 2.5 mg/kg, the objective response rate was 33.3%, the confirmed objective response rate was 29.6%, and median progression-free survival was 6.9 months.
All enrolled patients had previously progressed on a third-generation EGFR inhibitor, and nearly two-thirds had also received platinum-based chemotherapy.
Mandatory primary G-CSF prophylaxis was linked to an improved hematologic safety profile versus earlier reported experience; no treatment-related deaths occurred and one patient discontinued for a treatment-related adverse event.

DT Editorial Team·Sep 12, 2026·via medicalxpress.com